Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Scandal

Kobayashi Pharmaceutical Co. is considering a buyout offer exceeding ¥500 billion ($3.2 billion) from private equity investors. The company faced a supplement contamination issue that resulted in suspected deaths. The buyout discussions follow regulatory and public scrutiny of the company's products and operations.

Next story